Hyundai Bioscience Co Ltd
048410
Company Profile
Business description
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.
Contact
150 North-Ahyun Road
3rd Floor Academic Cooperation Building
Ehwa Women’s University
Seodaemun-gu
Seoul
KORT: +82 7070080114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
69
Stocks News & Analysis
stocks
Wide moat ASX share beats earnings guidance
Wide moat share continues to grow despite a challenging residential construction market.
stocks
Cheap with attractive yield: Fair Value lifted for retail REIT after earnings
Management expects both earnings and distributions to increase next year.
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.10 | 13.30 | -0.14% |
| CAC 40 | 8,726.03 | 11.10 | 0.13% |
| DAX 40 | 26,323.88 | 4.43 | 0.02% |
| Dow JONES (US) | 53,975.98 | 60.95 | -0.11% |
| FTSE 100 | 10,862.50 | 38.59 | -0.35% |
| HKSE | 25,937.49 | 269.46 | 1.05% |
| NASDAQ | 26,605.36 | 85.26 | -0.32% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,753.11 | 4.53 | -0.06% |
| S&P/ASX 200 | 9,232.60 | 17.00 | -0.18% |
| SSE Composite Index | 3,966.59 | 26.56 | 0.67% |